Mundipharma presents wealth of data for Penthrox®▼(methoxyflurane) at EUSEM Congress, demonstrating superiority compared to standard of care in trauma pain in adults
15 Oct 2019
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY
Swissmedic reviewing licence extension for the SGLT2 inhibitor Invokana® (canagliflozin) in fast-track procedure
10 Oct 2019
STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin
3 Sep 2019
Mundipharma Welcomes the New Guidelines from ESC/EASD Recommending First-Line use of Sodium-Glucose Co-transporter-2 Inhibitors for Type 2 Diabetes Patients with Cardiovascular Disease
3 Sep 2019
STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency
22 Aug 2019
FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA
Mundipharma announces exclusive license and supply agreement with Prestige Biopharma for Tuznue® (HD201)
2 Jul 2019
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
Invokana® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis
11 Jun 2019
STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
Mundipharma announces exclusive outsourcing distribution agreement with Egis Pharmaceuticals for Pelmeg▼® in Central and Eastern Europe
13 May 2019
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
Invokana® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study
16 Apr 2019
EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
